Retrophin (RTRX) PT Raised to $40 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
September 7, 2016 9:25 AM EDTCombined sparsentan treatment group experienced 44.8% reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint
Preliminary safety findings show sparsentan was generally safe and well-tolerated
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Retrophin, Inc. (NASDAQ: RTRX) today announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal... More
Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
September 7, 2016 6:55 AM EDTÂ Â Â Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint
Preliminary safety findings show sparsentan was generally safe and well-tolerated
Conference call scheduled for today at 8:30 a.m. ET
SAN DIEGO, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved... More
